Glioblastoma (Brain Cancer) Fund

The University of Liverpool’s Glioblastoma (Brain Cancer) Fund supports ground-breaking research into immunotherapy, a promising new treatment for glioblastoma.

Glioblastoma is the most common type of primary brain cancer.  Despite intensive treatment with surgery, radiotherapy & chemotherapy, people with glioblastoma on average lose 20 years of life – the highest average years of life lost compared to other cancers.

Immunotherapy is a new type of treatment that is revolutionising oncology by manipulating the body’s own immune system into fighting cancer. Researchers at the University of Liverpool working with The Walton Centre NHS Foundation Trust will study the immune system response in long-term survivors and compare the results with those patients who do not respond to treatment. 

The research will be led by Professor Michael Jenkinson, Professor of Neurosurgery at the University of Liverpool’s Department of Pharmacology and Therapeutics together with Dr Rasheed Zakaria and Professor Christian Ottensmeier.